Ubiquitination is an important protein modification that regulates diverse biological and pathological processes, including immune responses and oncogenesis 1,2 . A major function of ubiquitination is to target proteins to the proteasome for degradation, but many nondegradative functions have also been characterized 3, 4 . Ubiquitin conjugation is mediated by the sequential action of three enzymes, E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzymes and E3 ubiquitin ligases 3 . Different types of polyubiquitin chains can be formed through connection of the C-terminal glycine of a ubiquitin to any one of the seven internal lysine residues of the preceding ubiquitin 5 . Lys48 (K48)-linked polyubiquitin chains are the beststudied ubiquitin chains that target proteins for proteasomal degradation, whereas some other ubiquitin chains, such as the K63-linked polyubiquitin chains, can mediate nondegradative functions 4 . The specificity of protein ubiquitination is regulated by the E3 ubiquitin ligases, which exist in large numbers in mammalian cells and mediate substrate recognition 3, 6 .
Ubiquitination is an important protein modification that regulates diverse biological and pathological processes, including immune responses and oncogenesis 1, 2 . A major function of ubiquitination is to target proteins to the proteasome for degradation, but many nondegradative functions have also been characterized 3, 4 . Ubiquitin conjugation is mediated by the sequential action of three enzymes, E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzymes and E3 ubiquitin ligases 3 . Different types of polyubiquitin chains can be formed through connection of the C-terminal glycine of a ubiquitin to any one of the seven internal lysine residues of the preceding ubiquitin 5 . Lys48 (K48)-linked polyubiquitin chains are the beststudied ubiquitin chains that target proteins for proteasomal degradation, whereas some other ubiquitin chains, such as the K63-linked polyubiquitin chains, can mediate nondegradative functions 4 . The specificity of protein ubiquitination is regulated by the E3 ubiquitin ligases, which exist in large numbers in mammalian cells and mediate substrate recognition 3, 6 .
The E3 ubiquitin ligase MDM2 has been extensively studied as an oncogene product that mediates the ubiquitin-dependent degradation and functional inactivation of the tumor suppressor p53 (refs. 7,8) . Elevated MDM2 protein expression has been documented in a large variety of human cancers and is thought to result from gene amplification as well as transcriptional and post-translational regulation. Although the best-characterized target of MDM2 is p53, MDM2 has additional substrates 7 . Small-molecule inhibitors of MDM2, which block MDM2-p53 interaction or inhibit the ubiquitin ligase activity of MDM2, have been actively investigated in preclinical studies and clinical trials for the treatment of cancer 8, 9 . Although MDM2 has been extensively studied in cancer cells, its physiological role is relatively poorly understood. In particular, how MDM2 regulates immune responses is largely unclear.
Ubiquitination is a reversible reaction because the ubiquitin chains can be cleaved by a large family of ubiquitin-specific proteases, termed DUBs 10, 11 . DUBs can have specificity for both protein substrates and ubiquitin chains and, thereby, enable multiple ways to regulate protein ubiquitination. Like the E3 ubiquitin ligases, DUBs regulate diverse biological processes and are a class of drug targets [12] [13] [14] . However, the biological function of only a small proportion of DUBs has so far been characterized using physiological models, which hampers the development of DUB-based therapies. USP15 is a DUB that belongs to the ubiquitin-specific protease family 15 . In vitro studies have implicated USP15 in the regulation of signaling by TGF-β and survival of cancer cells in cell line models [16] [17] [18] . However, the physiological role of USP15, particularly the regulation of immune functions, has remained unclear. The molecular mechanism underlying the signaling function of USP15 is also incompletely understood.
In this work, we studied the function of USP15 using a genetargeting approach and identified USP15 as a negative regulator of T cell activation as well as a pivotal mediator of cancer-cell survival. We present biochemical and genetic evidence that USP15 functions by stabilizing the E3 ubiquitin ligase MDM2. In both activated T cells and cancer cells, loss of USP15 caused degradation of MDM2. MDM2 targeted a T cell transcription factor, NFATc2, and negatively regulated activation of T cells. USP15 deficiency promoted T cell responses to both bacterial infections and tumor-cell challenge. In cancer cells, USP15 stabilized MDM2 and regulated p53 responses. These results suggest that targeting USP15 may both induce tumor-cell apoptosis and boost antitumor T cell responses, and thus have important clinical applications.
RESULTS

USP15 is a negative regulator of T cell activation
Through analyses of the BioGPS database, we found that USP15 was abundantly expressed in immune cells (data not shown). We used a gene-targeting approach to investigate the physiological function of USP15 (Supplementary Fig. 1a-d) . The USP15 homozygous knockout (Usp15 −/− ) mice were born at expected Mendelian ratios and had comparable survival rate as the wild-type control mice (Supplementary Fig. 1e ). Usp15 −/− mice also did not show obvious abnormalities in thymocyte development or peripheral T cell homeostasis ( Supplementary Fig. 1f-i) . However, the USP15 deficiency promoted the T cell antigen receptor (TCR) and CD28-stimulated production of cytokines, such as interleukin 2 (IL-2) and interferon-γ (IFN-γ), in naive CD4 + T cells, as assessed by real-time quantitative reverse transcription-PCR (qRT-PCR; Fig. 1a) , intracellular cytokine staining (ICS; Fig. 1b ) and enzyme-linked immunosorbent assay (ELISA; Fig. 1c ). The loss of USP15 did not reduce the threshold of T cell responses but enhanced the cytokine induction at different doses of stimulation with anti-CD3 and anti-CD28 (Fig. 1d) . Induction of the effector T cell marker CD44, although not of the early activation marker CD69, was also enhanced in the USP15-deficient T cells ( Fig. 1e and data not shown). To examine whether USP15 has a T cell-intrinsic function in regulating activation of T cells, we reconstituted USP15-deficient T cells with USP15 by retroviral infection of T cell-depleted Usp15 −/− bone marrow cells and adoptive transfer into Rag1 −/− mice (Supplementary Fig. 2a ). Naive CD4 + T cells derived from the USP15-reconstituted bone marrow cells displayed reduced induction of IFN-γ (Supplementary Fig. 2b ). In contrast, reconstitution of the cells with a catalytically inactive USP15 mutant, C298A 19 , failed to suppress the induction of IFN-γ-producing cells (Supplementary Fig. 2b) . Thus, USP15 negatively regulates T cell cytokine production via its DUB function.
We next examined the role of USP15 in the regulation of CD4 + T cell differentiation by stimulating naive CD4 + T cells under T H 1 cell (10 µg/ml anti-IL4 and 10 ng/ml IL-12), T H 2 cell (10 µg/ml anti-IFN-γ and 20 ng/ml IL-4), T H 17 cell (10 µg/ml anti-IL4, 10 µg/ml anti-IFN-γ, 15 ng/ml IL-6 and 2.5 ng/ml TGF-β) and inducible regulatory T (iT reg ) cell (10 µg/ml anti-IL4, 10 µg/ml anti-IFN-γ and 1.5 ng/ml TGF-β) conditions. Under these standard T cell differentiation conditions, USP15-deficient and wild-type T cells were similar in differentiation and proliferation, although the USP15-deficient T cells had moderately enhanced apoptosis compared to wild-type T cells (Supplementary Fig. 2c-e) . However, in the presence of suboptimal doses (0.1 and 1 ng/ml) of IL-12 in T H 1 cell differentiation conditions, Usp15 −/− CD4 + T cells showed enhanced T H 1 cell differentiation (Fig. 1f) . We also examined whether USP15-deficient naive CD4 + T cells showed altered differentiation into iT reg cells. In the presence of a low concentration (0.5 ng/ml) of TGF-β and in the absence of an IFN-γ-blocking antibody, Usp15 −/− naive CD4 + T cells did not efficiently differentiate into iT reg cells; however, the USP15-deficient naive CD4 + T cells differentiated into iT reg cells normally in the presence of the IFN-γ-blocking antibody or a higher dose (1.5 ng/ml) of TGF-β (Supplementary Fig. 2f ). Moreover, wild-type and Usp15 −/− mice had comparable frequencies of T reg cells in peripheral lymphoid organs and thymus (Supplementary Fig. 2g ). Collectively, these results suggest that USP15 negatively regulates naive CD4 + T cell activation and T H 1 cell differentiation.
USP15 inhibits T cell responses to Listeria infection
To examine the in vivo role of USP15 in the regulation of T cell responses, we used a bacterial infection model known to induce strong T cell responses, particularly IFN-γ-producing CD4 + T cells 20 . In response to Listeria monocytogenes infection, both wild-type A r t i c l e s mice and Usp15 −/− mice generated IFN-γ-producing CD4 + T cells specific for the listeriolysin O (LLO) antigen (Fig. 2a) . However, Usp15 −/− mice had a higher frequency and absolute numbers of IFN-γ-producing CD4 + T cells than the wild-type mice, although the IFN-γ median fluorescence intensity (MFI) of the IFN-γ + T cells was comparable between the two genotypes ( Fig. 2a and Supplementary  Fig. 3a,b) . Moreover, serum concentration of IFN-γ was significantly increased in L. monocytogenes-infected Usp15 −/− mice compared to wild-type mice (Fig. 2b) . Consistent with their heightened T cell responses, the Usp15 −/− mice had a significantly lower bacterial load in the liver (Fig. 2c) .
To examine the CD4 + T cell-intrinsic function of USP15, we reconstituted T cell-deficient Tcrb −/− Tcrd −/− mice with wild-type or Usp15 −/− naive CD4 + T cells along with an equal number of wild-type CD8 + T cells. We did not detect differences in the spleen size or numbers of splenic CD4 + T cells between hosts reconstituted with wild-type and Usp15 −/− T cells under uninfected conditions after 4 d of T cell transfer ( Supplementary Fig. 3c-e) . However, after L. monocytogenes infection, hosts reconstituted with Usp15 −/− T cells had stronger immune responses, as indicated by a more profound spleen enlargement (Supplementary Fig. 3f ), increased numbers of splenic CD4 + T cells (Fig. 2d) and elevated serum IFN-γ (Fig. 2e) compared to host reconstituted with wild-type T cells. The L. monocytogenes-infected recipients of Usp15 −/− T cells also had significantly (two-tailed unpaired t-test; P < 0.05) higher numbers splenic CD11b + monocytes and CD11c + dendritic cells, consistent with increased activation and recruitment of myeloid cells by T cell-derived cytokines (Supplementary Fig. 3g ). In correlation with stronger immune responses, hosts reconstituted with Usp15 −/− T cells had reduced bacterial load in the liver (Fig. 2f) and increased survival rate (Fig. 2g) .
Because the L. monocytogenes strain used in our studies encodes chicken ovalbumin (LM-OVA), we crossed the Usp15 −/− mice with OT-II mice, which express a transgenic TCR specific for an OVA peptide, to generate Usp15 −/− OT-II mice and Usp15 +/+ OT-II littermate control mice. To test the effect of the USP15 deficiency on antigenspecific CD4 + T cell responses, we adoptively transferred naive CD4 + T cells isolated from Usp15 −/− OT-II mice and Usp15 +/+ OT-II littermates into B6.SJL mice and tracked donor and host T cells based on expression of the congenic markers CD45.2 and CD45.1, respectively. In response to LM-OVA infection, recipients of Usp15 −/− OT-II T cells produced a higher frequency (Fig. 2h,i ) and larger absolute numbers (Fig. 2j) of OVA-specific IFN-γ-producing OT-II T cells compared to mice that received Usp15 +/+ OT-II T cells. Moreover, mice that received Usp15 −/− OT-II T cells also had higher numbers of total splenic CD45.2 + T cells compared to mice that received Usp15 +/+ OT-II T cells upon challenge with LM-OVA, which suggested increased expansion of the Usp15 −/− OT-II T cells (Supplementary Fig. 3h ). In contrast, the number of T reg cells was similar in the recipients of Usp15 −/− OT-II cells and Usp15 +/+ OT-II T cells (Supplementary Fig. 3i ). Consistent with their T cell hyperactivation, mice transferred with Usp15 −/− OT-II T cells had lower L. monocytogenes load in the liver, which suggested a better ability to clear the bacteria (Fig. 2k) . These results suggest that USP15 is a negative regulator of T H 1 cell responses.
USP15 deficiency enhances NFATc2 activation in naive CD4 + T cells T cell activation involves cascades of signaling events triggered by the TCR and CD28 (ref. 21) . Upon stimulation with anti-CD3 plus anti-CD28, the Usp15 −/− and wild-type naive CD4 + T cells displayed similar TCR-proximal signaling events, including phosphorylation of the protein tyrosine kinases Lck and Zap70 ( Supplementary  Fig. 4a) , and downstream signaling events, such as phosphorylation of the MAP kinase Erk, the kinase Akt or the ribosomal S6 protein (Supplementary Fig. 4b ). Furthermore, although USP15 has been implicated as a mediator of TGF-β signaling in certain cancer cell lines 17, 18 , USP15-deficient T cells had normal TGF-β signaling, as evidenced by the comparable Smad phosphorylation, upregulation of Smad7 and downregulation of Myc in TGF-β-stimulated wildtype and Usp15 −/− T cells (Supplementary Fig. 4c,d) . Consistent After stimulation with TCR and CD28, USP15-deficient T cells showed increased nuclear expression of the transcription factor NFATc2 (Fig. 3a) , which mediates the induction of T cell-specific cytokines 22, 23 . The enhanced induction of NFATc2 nuclear expression in USP15-deficient T cells was not inhibited by TGF-β ( Supplementary  Fig. 4g ). Activation of NFATc1 and two major NF-κB members, c-Rel and p65, was similar in Usp15 −/− and wild-type T cells after stimulation with TCR and CD28 (Fig. 3a) . Overexpression of NFATc2 in EL4 T cells promoted the induction of IL-2 and IFN-γ ( Supplementary  Fig. 4h-j) . To examine the function of NFATc2 in mediating cytokine induction in Usp15 −/− naive CD4 + T cells, we used a bone marrow adoptive transfer approach. We transduced T cell-depleted Usp15 −/− bone marrow cells with a green fluorescent protein (GFP)-expressing lentiviral vector encoding a control or Nfatc2-specific short hairpin RNA (shRNA) and adoptively transferred the transduced cells into Rag1 −/− mice. Naive CD4 + T cells derived from bone marrow cells subjected to knockdown of NFATc2 expressed less IFN-γ and IL-2 than the naive CD4 + T cells derived from bone marrow cells subjected to knockdown using a control shRNA (Fig. 3b,c) .
We tested whether the hyperactivation of NFATc2 in Usp15 −/− T cells was due to enhanced nuclear translocation, expression or stabilization of NFATc2. Immunoblot (IB) assays revealed comparable cytoplasmic expression of NFATc2 in activated wild-type and Usp15 −/− T cells, despite their increased nuclear expression of NFATc2 (Fig. 3a) . Consistent with this result, the whole-cell level of NFATc2 was higher in activated USP15-deficient T cells compared to activated wild-type T cells (Fig. 3d) . USP15 deficiency did not enhance induction of Nfatc2 mRNA, as revealed by a qRT-PCR assay ( Supplementary Fig. 4k ). These results suggested that USP15 might regulate the stability of NFATc2. To examine this possibility, we stimulated T cells in the presence of a protein-synthesis inhibitor, cycloheximide (CHX). Treatment with CHX led to substantial loss of NFATc2 in wild-type T cells but not in the Usp15 −/− T cells (Fig. 3e) , which suggested that USP15 regulates degradation of NFATc2. Blocking protein degradation with a proteasome inhibitor, MG132, resulted in accumulation of NFATc2 in wild-type T cells, similar to that observed in USP15-deficient T cells (Fig. 3f) . We also observed abundant ubiquitination of NFATc2 in activated wild-type T cells after treatment with MG132, but not in activated Usp15 −/− T cells (Fig. 3g) . Ubiquitination of NFATc2 was very low in both wild-type and the Usp15 −/− T cells under resting conditions, and we could only detect it after extended immunoblot exposure ( Fig. 3g and data not shown). These data suggest that USP15 promotes the ubiquitination and degradation of activated NFATc2. Because NFATc2 is critical for mediating induction of T cell cytokines, including IL-2 and IFN-γ 22, 23 , these results provide a mechanistic insight for the increased production of cytokines in Usp15 −/− T cells.
USP15 regulates the stability of the E3 ubiquitin ligase MDM2
Because USP15 is a DUB, we investigated whether USP15 acts through regulating an E3 ubiquitin ligase of NFATc2. The E3 ubiquitin ligase MDM2 is known to induce NFATc2 ubiquitination in a breast cancer cell line 24 . Overexpression of MDM2 induced strong ubiquitination of NFATc2 in HEK293 cells (Fig. 4a) . To assess the role of MDM2 in T cells, we examined whether T cell activation altered MDM2 expression and whether MDM2 is regulated by USP15. Stimulation of naive CD4 + T cells by anti-CD3 plus anti-CD28 triggered induction of Mdm2 mRNA, which was similar in USP15-deficient and wild-type T cells (Fig. 4b) . Whereas stimulation with TCR and CD28 induced a transient loss of MDM2 protein in wild-type naive CD4 + T cells, this effect was enhanced and prolonged in Usp15 −/− naive CD4 + T cells (Fig. 4c) . Proteasome inhibitor MG132 prevented loss of MDM2 (Fig. 4d) and caused accumulation of ubiquitinated MDM2 with K48-linked polyubiquitin chains in Usp15 −/− naive CD4 + T cells (Fig. 4e) . These results suggest that USP15 prevents the ubiquitin-dependent degradation of MDM2 in activated T cells. 
A r t i c l e s
We next examined whether USP15 directly targets MDM2. When we coexpressed USP15 and MDM2 in HEK293 cells, they formed a stable complex, as detected by co-immunoprecipitation (co-IP) assays (Fig. 4f) . USP15 contains several structural domains: a large catalytic domain that covers about two-thirds of the molecule, a domain present in ubiquitin-specific protease (DUSP) and two ubiquitin-like (Ubl) domains, one of which is located within the catalytic domain 25 (Fig. 4f) . Domain-mapping studies revealed that two USP15 C-terminal truncation mutants, USP15 amino acids 1-941 and 1-583, lacking different lengths of the catalytic domain retained the ability to bind MDM2 (Fig. 4f ). An N-terminal truncation variant, USP15 amino acids 114-981, lacking the DUSP could bind MDM2, but several other USP15 variants (278-981, 470-981 and 580-981) with larger N-terminal truncations did not bind MDM2 (Fig. 4f) . These results suggested that the first Ubl domain of USP15 was important for its interaction with MDM2. Endogenous USP15 and MDM2 also formed a stable complex in naive CD4 + T cells, and this molecular interaction was not influenced by the TCR and CD28 signals (Fig. 4g) . We also detected an USP15-MDM2 association in p53-deficient T cells (Fig. 4h) . Both USP15 and MDM2 were predominantly located in the cytoplasm of naive CD4 + T cells, where they formed a complex (Supplementary Fig. 5a ). MDM2 was located in the cytoplasm in Usp15 −/− T cells as well (Supplementary Fig. 5b ). When we examined the subcellular localization of p53, this protein was barely detectable by IB in untreated naive CD4 + T cells (data not shown). However, we detected it in the cytoplasm and, to a lesser extent, in the nucleus, after treatment with MG132 (Supplementary Fig. 5c ). Stimulation with TCR and CD28 enhanced the amount of nuclear p53. These results suggest that USP15 physically interacts with MDM2 in a p53-independent manner.
Considering the USP15-MDM2 direct association and the role of USP15 in stabilizing MDM2 and inhibiting MDM2 ubiquitination in activated T cells (Fig. 4c-e) , we examined whether USP15 directly deubiquitinates MDM2. MDM2 was abundantly ubiquitinated when overexpressed in HEK293 cells, likely through autoubiquitination (Fig. 4i) . When we expressed MDM2 together with wild-type USP15, but not with the catalytically inactive USP15(C298A) variant, ubiquitination of MDM2 was potently inhibited (Fig. 4i) . A parallel HEK293 transfection experiment revealed that USP15 did not inhibit the ubiquitination of NFATc2 (Supplementary Fig. 5d ). In addition, USP15 directly deubiquitinated MDM2 in vitro, and this required the catalytic activity of USP15 (Fig. 4j) . Thus, USP15 appears to be a deubiquitinase of MDM2 that prevents ubiquitin-dependent degradation of MDM2.
MDM2 negatively regulates NFATc2 and T cell activation
Because MDM2 induced NFATc2 ubiquitination in transfected cells (Fig. 4a) , we tested whether endogenous MDM2 regulated the activation or the expression of NFATc2. We found that activation of wild-type T cells in the presence of a small-molecule inhibitor (HLI373), which blocks the ubiquitin ligase activity of MDM2 (ref. 26) , enhanced the accumulation of NFATc2 in the nucleus (Fig. 5a) . The MDM2 inhibitor did not affect the activation of several other transcription factors. Furthermore, HLI373 increased the amount of NFATc2 in the cell (Fig. 5b) and caused hyperinduction of IL-2 and IFN-γ in wild-type T cells (Fig. 5c) . In contrast, HLI373 did not appreciably enhance NFATc2 
Lysates Fig. 5e,f) , which suggested that the USP15 deficiency caused T cell hyperactivation via downregulation of MDM2 (Fig. 4c) .
A r t i c l e s activation or cytokine induction in Usp15 −/− T cells (Supplementary
To directly examine whether the lower MDM2 expression in USP15-deficient T cells contributed to the enhanced activation of NFATc2 and induction of cytokines, we used bone marrow adoptive transfer to express MDM2 in Usp15 −/− T cells. We transduced T cell-depleted Usp15 −/− bone marrow cells with a GFP-expressing retroviral vector or a vector encoding MDM2 and adoptively transferred the cells into Rag1 −/− mice. Expression of the exogenous MDM2 substantially reduced TCR and CD28-stimulated nuclear accumulation of NFATc2 and production of IFN-γ (Supplementary Fig. 5g-i) . Using the same approach, we found that reconstitution of Usp15 −/− naive CD4 + T cells with wild-type USP15, but not its variant with a C298A substitution, prevented TCR and CD28-induced loss of MDM2 and reduced activation of NFATc2 (Supplementary Fig. 5j ), which emphasized a cell-intrinsic role for USP15 in regulating MDM2 and NFATc2.
Although MDM2 is known as an inhibitor of p53 (ref. 27), MDM2 deficiency promoted NFATc2 accumulation and cytokine induction even in p53-deficient T cells, which suggested that the role of MDM2 in T cell regulation was independent of p53 ( Fig. 5d-f) . Another MDM2 inhibitor, Nutlin3, known to block the MDM2-p53 interaction without inhibiting the overall ubiquitin ligase activity of MDM2 (refs. 7,28) did not promote the activation of NFATc2 or the induction of cytokines in wild-type naive CD4 + T cells, although Nutlin-3 did enhance the induction of the p53 target gene Cdkn1a ( Supplementary  Fig. 5k,l) . These results suggest that MDM2 negatively regulates NFATc2 activation and cytokine induction in naive CD4 + T cells in a p53-independent manner.
We also noticed that wild-type CD8 + T cells had markedly lower expression of MDM2 than CD4 + T cells, which was due to reduced Mdm2 mRNA expression (Supplementary Fig. 6a,b) . Consistently, unlike the effect seen in naive CD4 + T cells, USP15 deficiency did not appreciably affect activation of NFATc2 or production of cytokines in naive CD8 + T cells (Supplementary Fig. 6c-e) , which emphasized the role of MDM2 in the negative regulation of NFATc2 activation and cytokine induction in T cells. Together, these results suggest that MDM2 functions as a negative regulator of NFATc2 in naive CD4 + T cells.
USP15 regulates MDM2 in cancer cells
USP15 is overexpressed in cancer cell lines, although its role in MDM2 regulation in these malignant cells has not been investigated 18, 29 . We found that USP15 was abundantly expressed in most of the melanoma and colorectal cancer cell lines analyzed (Supplementary Fig. 7a) . We examined the role of USP15 in the regulation of MDM2 stability and cancer-cell survival using two different cancer cell lines, the melanoma cell line A375 and the colorectal cancer cell line HCT116, both of which express wild-type p53 (refs. 30,31) . Knockdown of USP15 in A375 cells using two different shRNAs caused spontaneous reduction in MDM2 protein expression (Fig. 6a) without reducing the level of Mdm2 mRNA (Fig. 6b) . This phenotype differed from the degradation of MDM2 in primary T cells, which required the TCR and CD28 signals (Fig. 4c) . The spontaneous degradation of MDM2 appears to be specific for tumor cells because MDM2 protein was only slightly reduced in human primary fibroblasts subjected to USP15 knockdown (Supplementary Fig. 7b ) and not changed in Usp15 −/− mouse B cells or thymocytes (Supplementary Fig. 7c ).
In the melanoma and colorectal tumor cell lines analyzed, expression of NFATc2 was very low (data not shown). However, MDM2 downregulation in cells in which USP15 was knocked down resulted in upregulation of p53 and its target genes Cdkn1a and Bbc3 (Fig. 6a,c) , coupled with enhanced apoptosis (Fig. 6d,e) . These phenotypes of the cells that we subjected to USP15 knockdown were efficiently reversed upon reconstitution with a USP15 expression vector encoding an shRNA-resistant transcript (Supplementary Fig. 7d,e) . Knocking down USP15 in the colon cancer cell line HCT116 also caused downregulation of MDM2 and concomitant upregulation of p53 and p53 target genes as well as enhanced apoptosis (Fig. 6f,g ). These effects of USP15 knockdown were dependent on p53, because we detected them in wild-type, but not in p53-deficient, HCT116 cells ( Supplementary Fig. 7f,g) .
Incubation of A375 cells that we subjected to USP15 knockdown with a proteasome inhibitor (MG132) prevented the loss of MDM2 and caused accumulation of ubiquitinated MDM2 (Fig. 6h and  Supplementary Fig. 8a ), which suggested that, similar to the case in activated T cells, USP15 was required to prevent ubiquitin-dependent MDM2 degradation in cancer cells. Conversely, when we subjected HCT116 and A375 cells to USP15 knockdown and incubated them with CHX resulted in accelerated degradation of MDM2 and delayed degradation of p53 (Supplementary Fig. 8b) .
Recent studies suggest a role for USP15 in the regulation of TGF-β signaling in some cancer cell lines 17, 18 . However, knockdown of USP15 in A375 or HCT116 cells did not interfere with TGF-β-stimulated phosphorylation of Smad or induction of two TGF-β target Fig. 8c-e) . These results, together with the finding that USP15 deficiency had no effect on TGF-β signaling in T cells ( Supplementary Fig. 4c-g ), indicate that the function of USP15 in regulating TGF-β signaling may be cell type-specific. Thus, as seen in activated CD4 + T cells, USP15 is required for the stability of MDM2 in A375 melanoma cells and HCT116 colon cancer cells.
USP15 regulates both tumor growth and antitumor immunity
The findings that USP15 deficiency promotes T cell activation and cancer cell apoptosis indicated that inhibition of USP15 might suppress tumor growth both via a tumor cell-intrinsic mechanism and by enhancing the anti-tumor host defense. Knockdown of USP15 in A375 and HCT116 cells attenuated the growth of xenograft tumors in nude mice ( Fig. 7a and Supplementary Fig. 9a,b) . We did not see this effect in p53-deficient HCT116 cells ( Supplementary  Fig. 9c) . Furthermore, introduction of exogenous MDM2 in A375 cells in which USP15 was knocked down reduced the level of p53, promoted tumor growth and inhibited apoptosis ( Fig. 7b-d) . We next examined the role of USP15 in regulating antitumor host defenses in a B16 melanoma model 32 . Compared to wild-type mice, Usp15 −/− mice had a profound reduction in size of B16 tumors and tumor-induced lethality (Fig. 7e,f) . Knocking down USP15 in the B16 tumor cells revealed a combinatorial effect on tumor inhibition ( Supplementary Fig. 9d-f) . Compared to wild-type hosts, B16 cell-challanged Usp15 −/− mice had an increased frequency of IFN-γ + CD4 + T cells infiltrating to the tumors ( Fig. 7g and Supplementary Fig. 9g ). Despite the lack of a direct effect of USP15 deficiency on CD8 + T cell activation ( Supplementary  Fig. 6 ), B16 cell-challenged Usp15 −/− mice also had an increased frequency of tumor-infiltrating CD8 + effector T cells. This is probably due to increased activation and recruitment of CD8 + T cells to tumor site by the CD4 + T cells via different mechanisms, including the production of IFN-γ 33 . We also considered the potential involvement of T reg cells. Wild-type and Usp15 −/− mice had similar frequencies of T reg cells in both the lymphoid organs and the tumors (Supplementary Fig. 10a,b) . We next examined the role of IFN-γ-producing T cells in mediating tumor suppression. Injection of an IFN-γ neutralizing antibody in the Usp15 −/− mice promoted tumor growth, which suggested that IFN-γ contributes to the stronger anti-tumor immunity in Usp15 −/− mice ( Supplementary Fig. 10c ). To examine the T cell-intrinsic function of USP15 in regulating antitumor immunity, we reconstituted T cell-deficient Tcrb −/− Tcrd −/− mice with wild-type or Usp15 −/− naive CD4 + T cells along with wild-type CD8 + T cells and then challenged the recipient mice with B16 melanoma cells. Compared to hosts receiving wild-type T cells, mice receiving Usp15 −/− T cells were much more efficient in controlling melanoma growth (Fig. 7h) . When not challenged with the B16 melanoma cells, the mice receiving wild-type and Usp15 −/− T cells had similar numbers of splenic CD4 + T cells in the spleen (Supplementary Fig. 10d ). These findings suggest that USP15 inhibition may not only promote cancer cell apoptosis but also boost T cell-mediated antitumor immunity.
DISCUSSION
We identified USP15 as a negative regulator of T cell activation. USP15 deficiency promoted T cell activation in vitro and enhanced T cell responses in vivo to L. monocytogenes infection and tumor challenge. USP15 stabilized MDM2, which in turn mediated ubiquitindependent degradation of NFATc2 and negatively regulated T cell activation. USP15 also stabilized MDM2 in cancer cells, and regulated p53 function and cancer-cell survival. These findings suggest that targeting USP15 may both induce tumor-cell apoptosis and boost antitumor T cell responses.
MDM2 is known as an inhibitor of p53 and a mediator of cancer-cell survival; however, the role of MDM2 in the regulation of immune responses has remained poorly understood. Our data suggested a p53-independent function of MDM2 in the regulation of T cell activation. Notably, there are two different types of MDM2 inhibitors, which function by inhibiting the E3 ligase activity of MDM2 and interfering with the MDM2-p53 interaction, respectively. These two different types of MDM2 inhibitors had very different effects on T cell activation, which suggests possible differences in their therapeutic efficacies when used in combination with immunotherapeutic approaches. Because HLI373, but not Nutlin-3, promotes activation of T cells, the former may be ideal for use together with cancer immunotherapy.
Prior studies suggest that USP15 also regulates TGF-β signaling in certain cancer cell lines 17, 18 . Because TGF-β is an immunosuppressive cytokine, it raises the intriguing question of whether the negative role of USP15 in regulating T cell activation also involves altered TGF-β signaling. However, we did not detect an obvious npg defect of the USP15-deficient CD4 + T cells in TGF-β-stimulated phosphorylation of Smad or expression of target genes. These data suggest that the function of USP15 in regulating TGF-β signaling may be dependent on cell types and/or activation conditions. Future studies will examine this potential role of USP15 in different types of immune system cells. We found that USP15 mediates the stability of MDM2 in both T cells and cancer cells. USP15 functioned as a deubiquitinase of MDM2 because it bound to MDM2 and directly cleaved the ubiquitin chains from MDM2. Loss of USP15 in melanoma and colorectal cell lines caused spontaneous ubiquitination and degradation of MDM2, which suggested that the amount of MDM2 in cancer cells is maintained by a dynamic balance between ubiquitination and deubiquitination. In resting T cells, MDM2 was stable even in the absence of USP15; however, the TCR and CD28 signals stimulated ubiquitindependent degradation of MDM2, which was negatively regulated by USP15. How T cell activation signals trigger the degradation of MDM2 remains to be studied, but one possibility is that the TCR and CD28 signals stimulate the E3 ligase activity of MDM2, which causes both MDM2 self-ubiquitination and the ubiquitination of its targets. This hypothesis also explains why NFATc2 undergoes ubiquitination in activated T cells but not in resting T cells. In addition to USP15, USP7 has been implicated in the regulation of MDM2 in cancer cells. USP7 originally had been identified as a DUB that stabilizes p53, but subsequent studies suggest that USP7 also regulates MDM2 (refs. 34,35) . It is unknown whether USP7 also regulates functions of the immune system, particularly activation of T cells. Another intriguing question is whether USP15 and USP7 functionally cooperate in the regulation of MDM2. A protein-protein interaction screen study has revealed the physical interaction between USP15 and USP7, although the functional importance remains to be studied 36 .
Our findings have important implications for cancer therapy. Immunotherapy and targeted therapy are two promising approaches in the treatment of cancer 37 . It has been suggested that the combination of these approaches may represent a paradigm shift to greatly improve the clinical efficiencies. However, for the successful partnering of targeted therapy with immunotherapy, it is important that the drug targets are not required for immune system functions. Ideally, the anticancer drugs should also promote antitumor immunity. Our current findings suggest that USP15 may be an excellent drug target for partnering with immunotherapy. Future studies will directly examine this possibility using animal models of cancer therapy.
METHODS
Methods and any associated references are available in the online version of the paper. 
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The authors declare no competing financial interests. Plasmids. The retroviral expression vector for human USP15 (double-tagged with hemagglutinin (HA) and Flag) was purchased from Addgene (plasmid #22570) and used as template for creating the catalytically inactive USP15 variant, C298A, by site-directed mutagenesis. The originally reported USP15 variant, C269A, was named based on the sequence of USP15 isoform 2 cDNA 19 . This corresponding residue in USP15 isoform 1 is Cys298. Sequences encoding full-length USP15 isoform 1 and its truncated variants were subcloned into the HindIII and SalI sites of the p3×Flag vector by PCR using primers listed in Supplementary Table 2 . The expression vectors pcDNA-Xpress-His-USP15 (Addgene, #23216) and pcDNA-Xpress-His-USP15 C269A (Addgene, #23217) were used for production of recombinant proteins. These vectors encode USP15 isoform 2 (ref. 19 ). The USP15 vector encoding an shRNA-resistant transcript was produced by site-directed mutagenesis to introduce sense mutations at the shRNA-binding site of cDNA encoding USP15. Primers for site-directed mutagenesis are listed in Supplementary Table 3 . Sequences encoding USP15 and USP15(C298A) (no epitope tag) were cloned into a lentiviral vector. Human MDM2 (HDM2) plasmid was provided by W. Gu (Columbia University), and the cDNA encoding MDM2 was subcloned into the pMIGR1-GFP retroviral vector with an HA tag sequence. Mouse NFATc2 in the GFP-RV-DV retroviral vector was from Addgene. The shRNAs for human and mouse Usp15 and mouse Nfatc2 as well as a nonsilencing shRNA control (in the pGIPZ lentiviral vector) were from Thermo Scientific. The lentiviral packaging plasmids, and the HA-ubiquitin vector have been described previously 39 .
Antibodies and reagents. Antibodies used in this study are listed in Supplementary Table 4 , and additional antibodies for cell stimulation, immunoblot and flow cytometry were as described 39 . APC-annexin V, FITC-annexin V and propidium iodide (PI) staining solution were from BD Biosciences. IL-3, IL-6, stem cell factor, and hTGF-β were from R&D Systems, and IL-12 and IL-4 were from PeproTech. His-tagged human USP15 recombinant protein was from Enzo Life Sciences. His-USP15 and His-USP15(C269A) proteins were also produced by transfecting HEK293 cells with pcDNA-Xpress-His-USP15 and pcDNA-Xpress-His-USP15(C269A) and purified using His60 Ni Resin (Takara). HLI373 was from Tocris, and Nutlin-3 was from Cayman ((−)-Nutlin-3). CHX, phorbol 12-myristate 13-acetate (PMA) and ionomycin were from Sigma-Aldrich.
T cell isolation and stimulation. Primary T cells were isolated from the spleen and lymph nodes of female mice (6-8 weeks old) 40 . Naive CD4 + and CD8 + T cells were purified by flow cytometric cell sorting based on CD4 + CD44 lo CD62L hi and CD8 + CD44 lo surface markers, respectively. The cells were stimulated with plate-bound anti-CD3 (1 µg/ml) and anti-CD28 (1 µg/ml) in replicate wells of 96-well plates (1 × 10 5 cells per well) for ELISA, 12-well plates (1 × 10 6 cells per well) for qRT-PCR and 6-well plates (5 × 10 6
per well) for IB assays. Where indicated, the cells were acutely stimulated using an antibody cross-linking protocol 39 . For TGF-β stimulation, the T cells were preactivated for 24 h with anti-CD3 plus anti-CD28, starved for 24 h in low-serum (0.5%) medium and then stimulated with TGF-β (10 ng/ml).
CD4 + T cell differentiation. Naive CD4 + T cells were isolated from spleens and lymph nodes and stimulated with plate-bound anti-CD3 (1 µg/ml) and anti-CD28 (1 µg/ml) under T H 1 (10 µg/ml anti-IL4, 10 ng/ml IL-12), T H 2 (10 µg/ml anti-IFN-γ, 20 ng/ml IL-4), T H 17 (10 µg/ml anti-IL4, 10 µg/ml anti-IFN-γ, 15 ng/ml IL-6, 2.5 ng/ml TGF-β) and T reg (10 µg/ml anti-IL4, 10 µg/ml anti-IFN-γ, 1.5 ng/ml TGF-β) conditions. After 5 d of stimulation, the cells were subjected to ICS, ELISA or qRT-PCR analyses. The cells were also subjected to proliferation assays based on thymidine incorporation and apoptosis assays. In some experiments, different doses of IL-12 and TGF-β were used for the differentiation of T H 1 and T reg cells.
Flow cytometry, cell sorting and intracellular cytokine staining. Suspensions of splenic and lymph node cells were subjected to flow cytometry and cell sorting as described 40 using LSR II (BD Bioscience) and FACSAria (BD Bioscience) flow cytometers, respectively. The data were analyzed using FlowJo software. For ICS, the anti-CD3/anti-CD28-activated T cells were further stimulated for 4 h with PMA plus ionomycin in the presence of monensin and then subjected to intracellular IFN-γ staining and flow cytometry. For analyzing in vivo primed antigen-specific T cells, the T cells were stimulated in vitro with the indicated antigenic peptides in the presence of monensin and then subjected to ICS.
ELISA and quantitative reverse trancriptase-PCR. Supernatants of in vitro
cell cultures or sera of mice were analyzed by ELISA using a commercial assay system (eBioScience). Total RNA was prepared for the indicated cells and subjected to qRT-PCR 39 using gene-specific primers (Supplementary Table 5 ).
Immunoblot and ubiquitination assays. Total cell lysates or subcellular extracts were prepared and subjected to IB assays as described 41 . The Santa Cruz anti-USP15 (2D5) and the Proteintech anti-USP15 antibodies were used for detecting human and mouse USP15, respectively. The Millipore anti-MDM2 and the Sigma anti-MDM2 antibodies were used for detecting human and mouse MDM2, respectively. For ubiquitination assays, MDM2 and NFATc2 were isolated by IP under denaturing conditions 39 , and the ubiquitinated MDM2 and NFATc2 were detected by IB using a ubiquitin antibody specifically detecting K48-linked ubiquitin chains (Millipore). For transfection models, the expression vector encoding MDM2 or NFATc2 was transfected into HEK293 cells along with the HA-ubiquitin expression vector and the ubiquitinated MDM2 and NFATc2 were isolated by denaturing IP and detected by anti-HA IB. For deubiquitination assays, the isolated MDM2-ubiquitin conjugates were incubated with purified USP15 or its catalytic mutant in a deubiquitination buffer 42 for 4 h and then subjected to IB using anti-ubiquitin.
Cell culture, gene silencing and overexpression. Human melanoma cell line A375 and colon cancer cell line HCT116 were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS (FBS) and 1% penicillin/streptomycin. HCT116 p53 null (Trp53 −/− ) and wild-type control (Trp53 +/+ ) cells were provided by B. Vogelstein (Johns Hopkins University), and the normal human dermal fibroblasts were from PromoCell. Murine B16 melanoma cells stably transfected with OVA were provided by Q. Yi (Cleveland Clinic Foundation) 43 . For gene silencing, lentiviral particles were prepared as described 39 by transfecting HEK 293T cells with pLKO.1 or pGIPZ lentiviral vectors encoding specific shRNAs along with packaging plasmids. The packaged viruses were then used to infect the indicated cells, followed by selection of the infected cells by puromycin (1 µg/ml) for 7 d or by sorting GFP + cells (for the pGIPZ vector). For overexpression studies, lentiviral transduction was as described above, and retroviral packaging and transduction were as described previously 44 .
Bone marrow transduction and adoptive transfer. Bone marrow cells were taken from Usp15 −/− or wild-type control mice that were treated with 5-fluorouracil (150 mg/kg) for 48 h. 
